ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rolf Schoch who wrote ()	1/15/2000 1:52:00 AM
From: scott_jiminez	Read Replies (1) of 4474

A comparison of a number of Genome/Gene Therapy companies. 3 month performance Company Percent change Ariad (ARIA) 1132 Incyte (INCY) 578 Hyseq (HYSQ) 482 Celera (CRA) 480 Curagen (CRGN) 421 Genome Ther. (GENE) 389 Gene Logic (GLGC) 303 Myriad Gen. (MYGN) 236 Aurora Bio. (ABSC) 140 Visible Gene. (VGIN) 118 Genset (GENXY) 110 Human Gen.Sci.(HGSI) 104 Affymetrix (AFFX) 72 Millennium (MLNM) 62 Ariad's performance is extraordinary, nearly doubling the next best. The stock is more than simply following a sector rotation to the biotechs or a subsector focus on genomics/gene therapy. The stock is a clear standout in a very strong sector. This performance strongly suggests Ariad - more specifically ARGENT - is beginning to be recognized as a major player in the future. When a stock breaks out like this in a field that itself is breaking out, it often bodes extremely favorably for an extended period. To all long time Ariad longs: congratulations.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next